Affordable Access

deepdyve-link deepdyve-link
Publisher Website

A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer.

Authors
Type
Published Article
Journal
Investigational New Drugs
1573-0646
Publisher
Springer-Verlag
Publication Date
Volume
29
Issue
6
Pages
1482–1487
Identifiers
DOI: 10.1007/s10637-010-9478-3
PMID: 20596747
Source
Medline
License
Unknown

Abstract

The data suggest this is a well tolerated regimen with modest response rates but with time to progression and survival rates similar to those reported for paclitaxel alone and relatively high rates of stable disease in this sample of patients.

Statistics

Seen <100 times